JochenReiserMDPh.D.
Nephrology • Chicago, ILProfessor and Chairman of Medicine at Rush University Medical Center
Dr. Reiser is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1611 W. Harrison Street
Suite 510
Chicago, IL 60612Phone+1 312-942-6639Fax+1 312-942-5271- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 2003 - 2005
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2000 - 2003
University of Heidelberg Faculty of MedicineClass of 1998
Certifications & Licensure
IL State Medical License 2013 - 2026
FL State Medical License 2008 - 2013
MA State Medical License 2005 - 2010
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2009
Clinical Trials
- Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial Start of enrollment: 2008 Dec 01
- KIDney Injury in Times of COVID-19 (KIDCOV) Start of enrollment: 2021 Mar 01
Publications & Presentations
PubMed
- Obesity, Inflammation, and Clinical Outcomes in COVID-19: A Multicenter Prospective Cohort Study.Christina G Hutten, Kishan Padalia, Alexi Vasbinder, Yiyuan Huang, Anis Ismail, Ian Pizzo, Kristen Machado Diaz, Tonimarie Catalan, Feriel Presswalla, Elizabeth Anders...> ;The Journal of Clinical Endocrinology and Metabolism. 2024 Apr 18
- Correction: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin‑treated breast cancer patients: a prospective exploratory study.Wei, C., Banach, K., Chu, J., Tung, L., Atallah, I., Cobleigh, M., Rao, R., Feinstein, S., Usha, L., Reiser, J., Okwuosa, T.> ;Cardio-Oncology. 2024 Feb 6
- 1 citationsSoluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study.Wei, C., Banach, K., Chu, J., Tung, L., Cobleigh, M., Rao, R., Feinstein, S., Usha, L., Reiser, J., Okwuosa, T., Atallah, I.> ;Cardio-Oncology. 2024 Jan 15
- Join now to see all
Journal Articles
- Association Between Early Treatment with Tocilizumab and Mortality Among Critically Ill Patients with COVID-19Kusum S Mathews, Michal L Melamed, Samantha K Brenner, Amanda Leonberg-Yoo, Edward J Schenck, Jared Radbel, Jochen Reiser, Anip Bansal, Diana Finkel, Mary Mallappallil..., JAMA Internal Medicine
- Factors Associated with Death in Critically Ill Patients with Coronavirus Disease 2019 in the USKusum S Mathews, Michal L Melamed, Samantha K Brenner, Amanda Leonberg-Yoo, Edward J Schenck, Jared Radbel, Jochen Reiser, Anip Bansal, Alexandre M Shehata, Nitender G..., JAMA Internal Medicine
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Is Predictive of Non-AIDS Events During Antiretroviral Therapy-Mediated Viral SuppressionMichael M Lederman, Jochen Reiser, Clinical Infectious Diseases
Authored Content
- Factors Associated with Death in Critically Ill Patients with Coronavirus Disease 2019 in the USJuly 2020
- Factors Associated with Death in Critically Ill Patients with Coronavirus Disease 2019 in the USJuly 2020
- Factors Associated with Death in Critically Ill Patients with Coronavirus Disease 2019 in the USJuly 2020
- Soluble Urokinase Receptor and Acute Kidney InjuryJanuary 2020
- Join now to see all
Press Mentions
Study Uncovers New Immune Target to Treat AtherosclerosisDecember 16th, 2022- Scientists Discover New Immune Target to Treat Cardiovascular DiseaseDecember 16th, 2022
- New Immune Target to Treat Cardiovascular Disease DiscoveredDecember 15th, 2022
- Join now to see all
Hospital Affiliations
Rush University Medical CenterChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
